CTRI/2010/091/002922RecruitingPhase 3
A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Twice-Daily 0.01% Bimatoprost / 0.15% Brimonidine / 0.5% Timolol Ophthalmic Solution (Triple Combination) in Patients in India, Who Have Glaucoma or Ocular Hypertension With Elevated IOP, and are on Twice-Daily 0.2% Brimonidine / 0.5% Timolol Ophthalmic Solution (Dual Combination) Therapy
Allergan India Private Limited, Level 2, Prestige Obelisk, No. 3 Kasturba Road, Bangalore, Karnataka, IndiaAllergan, Inc., Irvine, California, USA0 sites120 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Enrollment
- 120
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Glaucoma and/or ocular hypertension in both eyes
- •-Requires IOP-lowering treatment in both eyes
Exclusion Criteria
- •-Other active ocular disease other than glaucoma or ocular hypertension (eg, uveitis, ocular infections or severe dry eye)
- •-Required chronic use of ocular medications other than study medications, except for intermittent use of artificial tears
- •-Use of oral, injectable or topical corticosteroids within 21 days
- •-Any eye laser surgery within 3 months
- •-Any intraocular surgery (eg, cataract surgery) within 6 months
Investigators
Similar Trials
Active, not recruiting
Phase 1
Safety and diagnostic Efficacy of Mangoral in Patients with abnormal liver cells and reduced kidney functioMRI in terms of visualization of detected focal liver lesions in patients with known or Suspected focal liver lesions and severe renal impairmentMedDRA version: 22.1Level: LLTClassification code 10028049Term: MRISystem Organ Class: 100000004848EUCTR2019-001599-12-ITAscelia Pharma AB197
Active, not recruiting
Phase 1
A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients with Known or Suspected Focal Liver Lesions and Severe Renal ImpairmentEUCTR2019-001599-12-SEAscelia Pharma AB197
Active, not recruiting
Phase 1
A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients with Known or Suspected Focal Liver Lesions and Severe Renal ImpairmentMRI in terms of visualization of detected focal liver lesions in patients with known or Suspected focal liver lesions and severe renal impairmentMedDRA version: 22.1Level: LLTClassification code 10028049Term: MRISystem Organ Class: 10022891 - InvestigationsEUCTR2019-001599-12-DEAscelia Pharma AB197
Active, not recruiting
Phase 1
A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients with Known or Suspected Focal Liver Lesions and Severe Renal ImpairmentEUCTR2019-001599-12-PLAscelia Pharma AB200
Recruiting
Phase 2
A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)fetal blood-disorder100381581000533010000211NL-OMON52622Janssen-Cilag International, NV1